Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for X4 Pharmaceuticals, Inc. (XFOR : NSDQ)
 
 • Company Description   
X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States.

Number of Employees: 83

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.16 Daily Weekly Monthly
20 Day Moving Average: 156,471 shares
Shares Outstanding: 30.82 (millions)
Market Capitalization: $35.76 (millions)
Beta: 0.62
52 Week High: $9.90
52 Week Low: $1.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.08% 1.27%
12 Week -27.04% -19.80%
Year To Date -49.35% -34.91%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
61 North Beacon Street 4th Floor
-
Boston,MA 02134
USA		 ph: 857-529-8300
fax: -		 investors@x4pharma.com http://www.x4pharma.com
 
 • General Corporate Information   
Officers
Paula Ragan - President and Chief Executive Officer
Michael S. Wyzga - Chairman of the Board of Directors
Adam S. Mostafa - Chief Financial Officer and Treasurer
William E. Aliski - Director
Gary J. Bridger - Director

Peer Information
X4 Pharmaceuticals, Inc. (CORR.)
X4 Pharmaceuticals, Inc. (RSPI)
X4 Pharmaceuticals, Inc. (CGXP)
X4 Pharmaceuticals, Inc. (BGEN)
X4 Pharmaceuticals, Inc. (GTBP)
X4 Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98420X103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/02/22
Share - Related Items
Shares Outstanding: 30.82
Most Recent Split Date: 3.00 (0.17:1)
Beta: 0.62
Market Capitalization: $35.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.66 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.43 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/02/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.72
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 44.62%
vs. Previous Quarter: 41.94%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -136.20
12/31/21 - -119.13
09/30/21 - -101.99
ROA
03/31/22 - -76.82
12/31/21 - -71.75
09/30/21 - -62.35
Current Ratio
03/31/22 - 4.73
12/31/21 - 6.27
09/30/21 - 6.10
Quick Ratio
03/31/22 - 4.73
12/31/21 - 6.27
09/30/21 - 6.10
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.61
12/31/21 - 2.61
09/30/21 - 2.78
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.60
12/31/21 - 0.51
09/30/21 - 0.48
Debt-to-Capital
03/31/22 - 37.49
12/31/21 - 33.97
09/30/21 - 32.48
 

Powered by Zacks Investment Research ©